40251 - 8th Tumor Models San Francisco Summit 2024

Following Merck announcing their goal to phase out animal use in their work, Astellas and MIMETAS expanding their partnership in immunotherapeutic development, and the domino effects across the field caused by the FDA Modernization Act 2.0, 2023 has set an exciting precedent for the upcoming year. However, the translation rates of oncology therapeutics into the clinic remain at 20%, proving there remains a large unmet need for tools to support drug development efforts in a patient-specific context at the preclinical and early translational levels.

At the 8th Annual Tumor Models San Francisco Summit, you will gain practical insights into the latest updates across the West Coast and beyond through 25+ case studies that will empower your candidate selection workflows. Join us to learn from and meet pioneers in preclinical and translational oncology to accelerate your candidate's clinical translatability with optimized efficiency, and cost-effectiveness!

What's in store?
Discover the rationale Amgen, IGM Biosciences, Rondo Therapeutics, and more implement across their model selection criteria to empower you to streamline your model selection processes.

Revolution Medicines spotlight the potential of genetically engineered models to enhance the therapeutic potential of RAS-targeted inhibitors

Uncover strategies to develop PDX models to support ADC studies at the preclinical stage through to preparation for an IND filing with Sutro Biopharma

Arsenal Biosciences demonstrate the applications of tumor models in cell therapy program development across multiple cancer indications

Characterize the complexities of the components of the tumor microenvironment by leveraging spatial biology and digital pathology tools with Takeda

URLs:
Brochure: https://go.evvnt.com/1948808-0?pid=2874
Website: https://go.evvnt.com/1948808-3?pid=2874

Category: Conferences | Health

Speakers: Alba Gonzalez-Junca - Associate Director - Arsenal Biosciences, Aldo Pourchet - Chief Executive Officer and Co-Founder - Omios Biologics, Alina Ainbinder - Principal Scientist - Takeda, Dayson Moreira - Senior Scientist Research Biology - Sutro Biopharma, Elsa Quintana - Senior Director, Cancer Immunology - Revolution Medicines, Felipe Vences-Catalán - Senior Scientist - Amgen, Jamie Cope - Senior Vice President, Research and Translational Medicine Development - Synchronity Pharma, Jessica Orf - Senior Scientist, Research Oncology - Gilead, Kelli Boyd - Senior Director, Pathology - Gilead, Kirk Johnson - Chief Scientific Officer - AmMax Bio, Ksenya Shchors - Senior Director, Scientific Strategy, Cell Therapy and Immuno-Oncology - Astellas, Liqin Liu - Senior Director IO - IGM Biosciences, Marco Campisi - Postdoctoral Fellow - Dana Farber Cancer Institute, Marie Ménard - Senior, Scientist I, Immuno-oncology - Revolution Medicines, Rachel Ames - Senior Scientist - RAPT Therapeutics, Raghava Sriramaneni - Scientist II, Cancer Immunology - CytomX Therapeutics, Robert Getzenberg - Medical Director Diagnostics Oncology - Astellas, Stephanie Casey Parks - Principal Scientist Oncology and Inflammation - Amgen, Subbaya Subramanian - Professor - University of Minnesota, Teresa Chiaverotti - Director, New Drug Development Research - SillaJen, Tim Sproul - Director - Earli, Udaya Rangaswamy - Director - Rondo Therapeutics, Venita De Almeida - Vice President, Program Development - 3T Biosciences, Vikash Bhagwandin - Founding Scientist Novel ADC Payloads - VincaStemyx, Zhenya Koliesnik - Senior Scientist - Synthekine Inc.